Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression

Navasona Krishnan, Xiaoying Chen, Diana Donnelly-Roberts, Eric G. Mohler, David M. Holtzman, Sujatha M. Gopalakrishnan

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia. The current treatment options for AD are limited to ameliorating cognitive decline temporarily and not reversing or preventing the progression of dementia. Hence, more effective therapeutic strategies are needed to combat this devastating disease. The low-density lipoprotein receptor has been shown to modulate the neuronal metabolism of cholesterol and apolipoprotein E, a major genetic risk factor for AD. LDLR overexpression in mice has been shown to increase amyloid-β clearance and reduce amyloid deposition. We conducted a phenotypic screen to identify novel signaling pathways and targets that regulate LDLR expression in glial cells using an annotated compound library of approximately 29000 compounds. The screen identified novel targets such as polo like kinase 1 (PLK1), activin receptor like kinase 5 (ALK5), and serotonin transporter (SERT). We used genetic, chemical biology and pathway analysis to confirm the target hypothesis. This work highlights that phenotypic screening is a promising strategy to identify novel mechanisms and targets for therapeutic intervention of complex neurodegenerative disorders.

Original languageEnglish
Pages (from-to)3262-3274
Number of pages13
JournalACS Chemical Biology
Volume15
Issue number12
DOIs
StatePublished - Dec 18 2020

Fingerprint

Dive into the research topics of 'Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression'. Together they form a unique fingerprint.

Cite this